Enhertu is part of a newer type of cancer treatment called antibody-drug conjugates (ADC). It works like a delivery system for medicine, even a "biologic missile." Imagine you're trying to deliver ...

WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...